capecitabine has been researched along with Adenocarcinoma, Clear Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, J; Basu, B; Brenton, J; Earl, H; Freeman, S; Gounaris, I; Hatcher, H; Hosking, K; Iddawela, M; Jimenez-Linan, M; Moyle, P; Parkinson, C; Sayal, K | 1 |
1 trial(s) available for capecitabine and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |